Madrigal Q2 FY26 net loss widens to $57.9 million; net sales rise 71% to $364.3 million

Reuters2026/07/30 11:21

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Madrigal posted 2Q 2026 net sales of $364.3 million, up 71% year over year.
Net loss widened to $57.9 million; loss per share widened to $1.99.
Operating expenses climbed to $420.6 million, including cost of sales of $40 million.
Cash, cash equivalents, restricted cash and marketable securities fell to $838.9 million as of June 30, 2026.
Patient count topped 49,000 as of June 30, 2026; Phase 1 dosing began for oral GLP-1 candidate MGL-2086 in June.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Madrigal Pharmaceuticals Inc. published the original content used to generate this news brief on July 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Madrigal Q2 FY26 net loss widens to $57.9 million; net sales rise 71% to $364.3 million

You may also like

Crypto prices